189 related articles for article (PubMed ID: 11528571)
21. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.
Taranger J; Trollfors B; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
J Infect Dis; 2000 Mar; 181(3):1010-3. PubMed ID: 10720524
[TBL] [Abstract][Full Text] [Related]
22. Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons.
Taranger J; Trollfors B; Bergfors E; Knutsson N; Sundh V; Lagergård T; Lind-Brandberg L; Zackrisson G; White J; Cicirello H; Fusco J; Robbins JB
Clin Infect Dis; 2001 Oct; 33(7):1004-10. PubMed ID: 11528572
[TBL] [Abstract][Full Text] [Related]
23. Does whole-cell pertussis vaccine protect black South African infants? Assessment of post-vaccination events and antibody responses to pertussis toxin, filamentous haemagglutinin and agglutinogens 2 and 3.
Ramkissoon A; Coovadia HM; Loening WE; Ndlovana M
S Afr Med J; 1991 Jun; 79(11):645-9. PubMed ID: 1675492
[TBL] [Abstract][Full Text] [Related]
24. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.
Hallander HO; Ljungman M; Jahnmatz M; Storsaeter J; Nilsson L; Gustafsson L
APMIS; 2009 Sep; 117(9):660-71. PubMed ID: 19703126
[TBL] [Abstract][Full Text] [Related]
25. Serologic response and antibody-titer decay in adults with pertussis.
Heininger U; Cherry JD; Stehr K
Clin Infect Dis; 2004 Feb; 38(4):591-4. PubMed ID: 14765356
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults.
Cherry JD; Chang SJ; Klein D; Lee M; Barenkamp S; Bernstein D; Edelman R; Decker MD; Greenberg DP; Keitel W; Treanor J; Ward JI
Clin Infect Dis; 2004 Dec; 39(11):1715-8. PubMed ID: 15578376
[TBL] [Abstract][Full Text] [Related]
27. Assessment of serum anti-Bordetella pertussis antibody titers among medical staff members.
Higa F; Haranaga S; Tateyama M; Hibiya K; Yamashiro T; Nakamatsu M; Tomoyose T; Nagahama M; Okamura T; Owan T; Kuda T; Kinjo F; Fujita J
Jpn J Infect Dis; 2008 Sep; 61(5):371-4. PubMed ID: 18806344
[TBL] [Abstract][Full Text] [Related]
28. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
29. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants.
Knuf M; Schmitt HJ; Wolter J; Schuerman L; Jacquet JM; Kieninger D; Siegrist CA; Zepp F
J Pediatr; 2008 May; 152(5):655-60, 660.e1. PubMed ID: 18410769
[TBL] [Abstract][Full Text] [Related]
30. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
[TBL] [Abstract][Full Text] [Related]
31. Kinetics of pertussis immune responses to tetanus-diphtheria-acellular pertussis vaccine in health care personnel: implications for outbreak control.
Kirkland KB; Talbot EA; Decker MD; Edwards KM
Clin Infect Dis; 2009 Aug; 49(4):584-7. PubMed ID: 19589084
[TBL] [Abstract][Full Text] [Related]
32. Comparison of a three-component acellular pertussis vaccine with whole cell pertussis vaccine in two-month-old children.
Pichichero ME; Green JL; Francis AB; Marsocci SM; Lynd AM; Litteer T
Pediatr Infect Dis J; 1994 Mar; 13(3):193-6. PubMed ID: 8177626
[TBL] [Abstract][Full Text] [Related]
33. The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP.
Robbins JB; Schneerson R; Keith JM; Shiloach J; Miller M; Trollors B
Vaccine; 2007 Apr; 25(15):2811-6. PubMed ID: 17291636
[TBL] [Abstract][Full Text] [Related]
34. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
[TBL] [Abstract][Full Text] [Related]
35. Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial.
Blennow M; Granström M; Jäätmaa E; Olin P
Pediatrics; 1988 Sep; 82(3):293-9. PubMed ID: 3043367
[TBL] [Abstract][Full Text] [Related]
36. Cellular immunity in adolescents and adults following acellular pertussis vaccine administration.
Meyer CU; Zepp F; Decker M; Lee M; Chang SJ; Ward J; Yoder S; Bogaert H; Edwards KM
Clin Vaccine Immunol; 2007 Mar; 14(3):288-92. PubMed ID: 17267589
[TBL] [Abstract][Full Text] [Related]
37. Clinical and serological reactions after immunization of children in Ghana, West Africa, with the Japanese acellular pertussis vaccine.
Biritwum RB; Isomura S; Ofosu-Amaah S; Sato Y
Dev Biol Stand; 1985; 61():539-43. PubMed ID: 2872130
[TBL] [Abstract][Full Text] [Related]
38. An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates.
Rothstein EP; Anderson EL; Decker MD; Poland GA; Reisinger KS; Blatter MM; Jacobson RM; Mink CA; Gennevois D; Izu AE; Sinangil F; Langenberg AG
Vaccine; 1999 Aug; 17(23-24):2999-3006. PubMed ID: 10462235
[TBL] [Abstract][Full Text] [Related]
39. The 1993 epidemic of pertussis in Cincinnati. Resurgence of disease in a highly immunized population of children.
Christie CD; Marx ML; Marchant CD; Reising SF
N Engl J Med; 1994 Jul; 331(1):16-21. PubMed ID: 8202096
[TBL] [Abstract][Full Text] [Related]
40. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.
McIntyre PB; Turnbull FM; Egan AM; Burgess MA; Wolter JM; Schuerman LM
Vaccine; 2004 Dec; 23(3):380-5. PubMed ID: 15530684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
